Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acticor Biotech SAS (ALACT.PA)

Paris - Paris Delayed Price. Currency in EUR
7.10+0.20 (+2.90%)
At close: 04:38PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.90
Open6.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.88 - 7.16
52 Week Range4.50 - 9.39
Volume3,432
Avg. Volume1,399
Market Cap74.488M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ALACT.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Acticor Biotech Announces Its Financial Agenda for The 1st Half of 2023

      PARIS, December 01, 2022--Regulatory News: Acticor Biotech (Euronext Growth Paris - ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company, a spin-off of INSERM, developing an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic strokes, today announces its financial agenda for the 1st half of 2023.

    • Business Wire

      Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

      PARIS, November 22, 2022--Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

    • Business Wire

      Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of October 31, 2022

      PARIS, November 07, 2022--Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today discloses the total number of voting rights and shares as of October 31, 2022 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

    Advertisement
    Advertisement